SILVER SPRING, Md. – The U.S. Food and Drug Administration (FDA) has launched a new initiative to expand drug quality testing, using samples purchased from retail pharmacies and wholesale distributors to identify potential problems with medications available to American consumers.
Announced Wednesday, November 18, the Enhanced Approach for Sampling and Testing (EAST) initiative combines modern screening techniques with traditional testing methods to evaluate more drug products and detect quality issues faster.
The program expands testing across manufacturers, therapeutic classes, and geographic regions, including drugs manufactured in the United States and abroad.
Testing will focus on three key quality measures: identity, to confirm that products contain the correct active pharmaceutical ingredient; purity, to identify impurities; and potency, to verify that medications contain the appropriate amount of active ingredient.
“The EAST initiative gives us an enhanced way to monitor drug quality across an increasingly complex global supply chain,” said Michael Kopcha, director of the FDA’s Office of Pharmaceutical Quality.
Under the program, drug samples requiring further evaluation will undergo confirmatory testing using established analytical methods, including those described in the United States Pharmacopeia.
The FDA said that testing results will help identify potential drug quality risks, determine whether regulatory action is necessary, and guide future inspections.
According to the agency, EAST is designed to expand surveillance across the pharmaceutical supply chain without increasing resource requirements or disrupting patients’ access to medications.
Testing results will be published through the FDA’s Drug Quality Sampling and Testing Programs website.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release